I'm Joe Gradyton and I'm Terry Grady. Welcome to this podcast of the People's Pharmacy.

You can find previous podcasts and more information on a range of health topics at people's pharmacy.com.

For centuries philosophers have been debating what makes a good life.

Now a long-running study offers answers.

This is the People's Pharmacy with Terry and Joe Grayden. Since 1938, the Harvard Study of Adult Development has periodically contacted its original

cohorts and their partners in offspring.

Almost all of these people filled out detailed questionnaires.

What does science show us about the factors that produce happiness? One key to a meaningful life is connecting with other people

and paying attention to their needs, not just your own.

How much of our happiness is under our control?

Coming up on the People's Pharmacy, whatlines, the Food and Drug Administration has just announced that it's authorized a second byvalent booster vaccination for at-risk individuals.

That includes people over 65 and immunocompromised patients.

The Pfizer Bioin Tech and Moderna Bivalent Boosters will protect against the original COVID-19 virus,

as well as the Omicron BA-4 and B-A-5 strains. Older Americans can get a second bivalient booster if at least four

months have passed since their first booster. Those who are immunocompromised need wait only

two months following a prior booster.

The FDA is recommending that vulnerable populations consider a second booster because immunity

fades after several months, and the second shot can reestablish some protection.

The Institute for Clinical and Economic Review, or ICER, has just issued a report questioning the value of the newest Alzheimer disease drug.

The FDA approved Lekemby, known by the generic name the Canomab in January. At the time headlines proclaimed the drug

an important advance in the treatment of dementia, but the new report

titled Beta Amyloid Antoid antibodies for early Alzheimer's disease paints a far less rosy picture.

...